Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04359108
Other study ID # IRB00228932
Secondary ID 1R01EY029741-01A
Status Recruiting
Phase N/A
First received
Last updated
Start date March 16, 2021
Est. completion date July 30, 2024

Study information

Verified date June 2024
Source Johns Hopkins University
Contact Seth Billings, Ph.D.
Phone 4437787462
Email seth.billings@jhuapl.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is driven by the hypothesis that navigation for users of retinal prosthetics can be greatly improved by incorporating Spatial Localization and Mapping (SLAM) and object recognition technology conveying environmental information via a retinal prosthesis and auditory feedback. The investigators will study how effectively the SLAM technology enables the visual prosthesis system to construct a map of the user's environment and locate the user within that map. The technology will be tested both with normally sighted individuals donning a virtual reality headset and with retinal prosthesis users (Argus II).


Description:

About 1.3 million Americans aged 40 and older are legally blind, a majority because of diseases with onset later in life, such as glaucoma and age-related macular degeneration. Second Sight Medical Products (SSMP) has developed the world's first FDA approved retinal implant, Argus II, intended to restore some functional vision for people suffering from retinitis pigmentosa (RP). In this era of smart devices, generic navigation technology, such as GPS mapping apps for smartphones, can provide directions to help guide a blind user from point A to point B. However, these navigational aids do little to enable blind users to form an egocentric understanding of the surroundings, are not suited to navigation indoors, and do nothing to assist in avoiding obstacles to mobility. The Argus II, on the other hand, provides blind users with a limited visual representation of their surroundings that improves users' ability to orient themselves and traverse obstacles, yet lacks features for high-level navigation and semantic interpretation of the surroundings. The proposed study aims to address these limitations of the Argus II through a synergy of state-of-the-art simultaneous localization and mapping (SLAM) and object recognition technologies. This study is driven by the hypothesis that navigation for users of retinal prosthetics can be greatly improved by incorporating SLAM and object recognition technology conveying environmental information via a retinal prosthesis and auditory feedback. SLAM enables the visual prosthesis system to construct a map of the user's environment and locate the user within that map. The system then provides object location and navigational cues via appropriate sensory modalities enabling the user to mentally form an egocentric map of the environment. Investigators will develop and test a visual prosthesis system which 1) constructs a map of unfamiliar environments and localizes the user using SLAM technology 2) automatically identifies navigationally-relevant objects and landmarks using object recognition and 3) provides sensory feedback for navigation, obstacle avoidance, and object/landmark identification.


Recruitment information / eligibility

Status Recruiting
Enrollment 35
Est. completion date July 30, 2024
Est. primary completion date July 30, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Criteria for inclusion of normally sighted individuals: - Subject speaks English; - Subjects must be an adult (at least 18 years of age); - Subject has the cognitive and communication ability to participate in the study (i.e., follow spoken directions, perform tests, and give feedback); - Subject is willing to conduct psychophysics testing up to 4-6 hours per day of testing on 3-5 consecutive days; - Subject has visual acuity of 20/40 or better (corrected); - Subject is capable of understanding participant information materials and giving written informed consent. - Subject is able to walk unassisted Criteria for inclusion of Argus II users: The inclusion criteria for the study are the following: - Subject is at least 25 years of age; - Subject has been implanted with the Argus II system; - Subject's eye has healed from surgery and the surgeon has cleared the subject for programming; - Subject has the cognitive and communication ability to participate in the study (i.e., follow spoken directions, perform tests, and give feedback); - Subject is willing to conduct psychophysics testing up to 4-6 hours per day of testing on 3-5 consecutive days; - Subject is capable of understanding patient information materials and giving written informed consent; - Subject is able to walk unassisted. Exclusion criteria for all subjects is the following: - Subject is unwilling or unable to travel to testing facility for at least 3 days of testing within a one-week timeframe; - Subject does not speak English; - Subject has language or hearing impairment.

Study Design


Intervention

Device:
Navigation System for Users of a Visual Prosthesis
We use common psychophysical judgments such as the following: discriminating between two alternatives by saying which is present in the field of view, touching a tablet computer to indicate the apparent location of a target in the frontal plane, and looking for targets by rotating the head and pointing when one is found. We will compare user performance using the Basic system with user performance using the Augmented and Augmented + Modal systems where contextual information associated with the task is conveyed to users via enhanced visual, auditory, and haptic modalities.

Locations

Country Name City State
United States Johns Hopkins Medicine - Wilmer Eye Institute Baltimore Maryland
United States Johns Hopkins Applied Physics Laboratory Laurel Maryland

Sponsors (3)

Lead Sponsor Collaborator
Johns Hopkins University Carnegie Mellon University, National Eye Institute (NEI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Accuracy as assessed as ratio of target identification success to total trials The participant will be asked to identify intended targets in a closed environment, as well as to navigate to intended targets. We will measure accuracy as the total number of successes divided by the total number of trials. Up to 5 minutes
Primary Trial Time as assessed by mean time duration to identify target This will be assessed by the mean duration of time to identify intended target (in seconds). For successful trials, the shorter the amount of time to conduct a task, the better the performance on said task. Up to 5 minutes
Primary Success in psychophysical judgments This will be assessed by the metric error in distance judgment, that is, the correctness of identification of judgments of target features. Measurement in meters. Trial Duration: estimated at up to one minute.
See also
  Status Clinical Trial Phase
Recruiting NCT01432847 - Cell Collection to Study Eye Diseases
Completed NCT04983914 - Retrospective NIS to Evaluate the Patient Benefit of TES
Recruiting NCT03845218 - Retinitis Pigmentosa Clinical Measures and Repeatability Testing of Potential Outcome Measures
Completed NCT00231010 - Molecular Genetics of Retinal Degenerations
Active, not recruiting NCT04611503 - PDE6A Gene Therapy for Retinitis Pigmentosa Phase 1/Phase 2
Completed NCT02909985 - Visual Activity Evoked by Infrared in Humans After Dark Adaptation N/A
Recruiting NCT01914913 - Clinical Study to Evaluate Safety and Efficacy of BMMNC in Retinitis Pigmentosa Phase 1/Phase 2
Completed NCT01949623 - Biomarkers In Retinitis Pigmentosa (BIRP) N/A
Completed NCT01835002 - Transcorneal Electrical Stimulation - Multicenter Safety Study N/A
Completed NCT00407602 - Argus® II Retinal Stimulation System Feasibility Protocol N/A
Completed NCT00515814 - Retina Implant Pilot Trial to Evaluate Safety & Efficacy in Blind Patients Having Degenerated Photo-receptors N/A
Completed NCT00100230 - DHA and X-Linked Retinitis Pigmentosa Phase 2
Active, not recruiting NCT00378742 - Repository for Inherited Eye Diseases
Terminated NCT05085964 - An Open-Label Extension Study to Evaluate Safety & Tolerability of QR-421a in Subjects With Retinitis Pigmentosa Phase 2
Recruiting NCT05805007 - Safety and Tolerability Study of Gene Editing Drug ZVS203e in Participants With Retinitis Pigmentosa Early Phase 1
Recruiting NCT05909488 - Role of UC-MSC and CM to Inhibit Vision Loss in Retinitis Pigmentosa Phase I/II Phase 2/Phase 3
Recruiting NCT06291935 - Safety and Tolerability of Intravitreal Administration of VG901 in Patients With Retinitis Pigmentosa Due to Mutations in the CNGA1 Gene Phase 1
Recruiting NCT03078309 - The Effects of Cannabis on Visual Functions in Healthy and Retinitis Pigmentosa Patients Early Phase 1
Completed NCT04238858 - Effects of Subtenon-injected Autologous Platelet-rich Plasma on Visual Functions in Eyes With Retinitis Pigmentosa N/A
Active, not recruiting NCT01680510 - The Effect of Oral Administration of 9-cis β Carotene Rich Powder of the Alga Dunaliella Bardawil Phase 1/Phase 2